Muscle creatine kinase/SV40 hybrid promoter for muscle-targeted long-term transgene expression - PubMed (original) (raw)
Affiliations
- PMID: 17203206
Muscle creatine kinase/SV40 hybrid promoter for muscle-targeted long-term transgene expression
Fumihiko Takeshita et al. Int J Mol Med. 2007 Feb.
Abstract
Gene therapy for congenital protein deficiencies requires lifelong expression of a deficient protein. Current gene therapy approaches preferentially employ the strong cytomegalovirus (CMV) promoter/enhancer or its derivative CAG promoter; however, these promoters provide only temporary transgene expression. To create a promoter that enables long-lasting expression in muscle, hybrid promoters were constructed by coupling the muscle creatine kinase (MCK) enhancer to various strong promoters for enhancement of tissue specificity and improved transcriptional activity. A hybrid promoter containing the MCK enhancer and the simian virus 40 promoter (MCK/SV40 promoter) yielded long-term (>6 months) expression of a human secretory alkaline phosphatase (huSEAP) reporter gene following electrotransfer of the plasmid into mice, whereas expression using a conventional CMV or CAG promoter faded away within a few weeks. To explore the mechanism behind the sustained expression obtained with the MCK/SV40 promoter, mice were immunized with a LacZ expression plasmid driven by MCK/SV40 or a conventional promoter. Minimal cellular and humoral responses to LacZ were observed in MCK/SV40 promoter-treated animals, and mouse SEAP gene expression in vivo was successfully maintained by both the MCK/SV40 and conventional promoters. These results suggest that the lower immunogenicity of the MCK/SV40 promoter contributed to long-lasting gene expression in mice. Therefore, the MCK/SV40 promoter may provide the basis for development of an effective transgene expression cassette for treatment of congenital protein deficiencies in which therapeutic proteins are recognized as foreign by the host immune system.
Similar articles
- Comparison of promoter region constructs for in vivo intramuscular expression.
Fabre EE, Bigey P, Orsini C, Scherman D. Fabre EE, et al. J Gene Med. 2006 May;8(5):636-45. doi: 10.1002/jgm.878. J Gene Med. 2006. PMID: 16477670 - Construction and analysis of compact muscle-specific promoters for AAV vectors.
Wang B, Li J, Fu FH, Chen C, Zhu X, Zhou L, Jiang X, Xiao X. Wang B, et al. Gene Ther. 2008 Nov;15(22):1489-99. doi: 10.1038/gt.2008.104. Epub 2008 Jun 19. Gene Ther. 2008. PMID: 18563184 - Transcriptional targeting to brain cells: Engineering cell type-specific promoter containing cassettes for enhanced transgene expression.
Boulaire J, Balani P, Wang S. Boulaire J, et al. Adv Drug Deliv Rev. 2009 Jul 2;61(7-8):589-602. doi: 10.1016/j.addr.2009.02.007. Epub 2009 Apr 23. Adv Drug Deliv Rev. 2009. PMID: 19394380 Review. - Plasmid DNA electrotransfer for intracellular and secreted proteins expression: new methodological developments and applications.
Bloquel C, Fabre E, Bureau MF, Scherman D. Bloquel C, et al. J Gene Med. 2004 Feb;6 Suppl 1:S11-23. doi: 10.1002/jgm.508. J Gene Med. 2004. PMID: 14978747 Review.
Cited by
- Of rAAV and Men: From Genetic Neuromuscular Disorder Efficacy and Toxicity Preclinical Studies to Clinical Trials and Back.
Buscara L, Gross DA, Daniele N. Buscara L, et al. J Pers Med. 2020 Nov 28;10(4):258. doi: 10.3390/jpm10040258. J Pers Med. 2020. PMID: 33260623 Free PMC article. Review. - A high-throughput screening and computation platform for identifying synthetic promoters with enhanced cell-state specificity (SPECS).
Wu MR, Nissim L, Stupp D, Pery E, Binder-Nissim A, Weisinger K, Enghuus C, Palacios SR, Humphrey M, Zhang Z, Maria Novoa E, Kellis M, Weiss R, Rabkin SD, Tabach Y, Lu TK. Wu MR, et al. Nat Commun. 2019 Jun 28;10(1):2880. doi: 10.1038/s41467-019-10912-8. Nat Commun. 2019. PMID: 31253799 Free PMC article. - Prolonged in vivo expression and anti-tumor response of DNA-based anti-HER2 antibodies.
Hollevoet K, De Smidt E, Geukens N, Declerck P. Hollevoet K, et al. Oncotarget. 2018 Feb 6;9(17):13623-13636. doi: 10.18632/oncotarget.24426. eCollection 2018 Mar 2. Oncotarget. 2018. PMID: 29568382 Free PMC article. - ADAR1 deaminase contributes to scheduled skeletal myogenesis progression via stage-specific functions.
Hsieh CL, Liu H, Huang Y, Kang L, Chen HW, Chen YT, Wee YR, Chen SJ, Tan BC. Hsieh CL, et al. Cell Death Differ. 2014 May;21(5):707-19. doi: 10.1038/cdd.2013.197. Epub 2014 Jan 17. Cell Death Differ. 2014. PMID: 24440912 Free PMC article. - An adeno-associated virus vector efficiently and specifically transduces mouse skeletal muscle.
Murakami I, Takeuchi T, Mori-Uchino M, Mori S, Fujii T, Aoki D, Nakagawa K, Kanda T. Murakami I, et al. Mol Biotechnol. 2011 Sep;49(1):1-10. doi: 10.1007/s12033-010-9369-z. Mol Biotechnol. 2011. PMID: 21197588
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources